Ofatumumab Biosimilar – Anti-MS4A1, CD20 mAb – Research Grade

Description of Ofatumumab Biosimilar - Anti-MS4A1, CD20 mAb - Research Grade

Introduction

Ofatumumab Biosimilar, also known as Anti-MS4A1, CD20 mAb, is a monoclonal antibody that has been developed as a biosimilar to the FDA-approved drug, Ofatumumab, for the treatment of multiple sclerosis (MS). This biosimilar is a research grade version of Ofatumumab, which means that it is intended for use in pre-clinical and early stage clinical research studies. In this article, we will discuss the structure, activity, and potential applications of Ofatumumab Biosimilar in the field of MS research.

Structure of Ofatumumab Biosimilar

Ofatumumab Biosimilar is a recombinant humanized monoclonal antibody that targets the CD20 protein, which is found on the surface of B cells. It is composed of two identical light chains and two identical heavy chains, each with a molecular weight of approximately 25 kDa. The antibody has a Y-shaped structure, with two Fab regions that bind to the CD20 protein and one Fc region that is responsible for the effector functions of the antibody.

Activity of Ofatumumab Biosimilar

The main activity of Ofatumumab Biosimilar is its ability to bind to the CD20 protein on the surface of B cells. This binding leads to the depletion of B cells through various mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis. By depleting B cells, Ofatumumab Biosimilar can reduce inflammation and prevent the progression of MS.

In addition to its direct effects on B cells, Ofatumumab Biosimilar also has immunomodulatory properties. It has been shown to inhibit the production of pro-inflammatory cytokines, such as TNF-α and IL-6, and promote the production of anti-inflammatory cytokines, such as IL-10. This dual mechanism of action makes Ofatumumab Biosimilar a promising therapeutic agent for the treatment of MS.

Potential Applications of Ofatumumab Biosimilar

Ofatumumab Biosimilar has shown promising results in pre-clinical and early stage clinical studies for the treatment of MS. It has been shown to reduce the number of relapses and delay the progression of disability in patients with relapsing-remitting MS. In addition, it has been found to be well-tolerated and safe, with a low incidence of adverse events.

Apart from its potential as a standalone therapy, Ofatumumab Biosimilar may also have a role in combination therapy for MS. Studies have shown that it can enhance the efficacy of other MS drugs, such as interferon-β and glatiramer acetate, when used in combination. This could lead to improved outcomes for patients with MS and provide a new treatment option for those who do not respond well to current therapies.

Conclusion

Ofatumumab Biosimilar, also known as Anti-MS4A1, CD20 mAb, is a research grade version of Ofatumumab that has shown promising results in the treatment of MS. Its unique structure and dual mechanism of action make it a promising therapeutic agent for the management of this debilitating disease. Further research is needed to fully understand the potential applications of Ofatumumab Biosimilar and its role in the treatment of MS.

SDS-PAGE for Ofatumumab Biosimilar - Anti-MS4A1, CD20 mAb

Ofatumumab Biosimilar - Anti-MS4A1, CD20 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.